Publication:

Current status of xenotransplantation and prospects for clinical application

Loading...
Thumbnail Image

Date

2009

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley-Blackwell
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Pierson, Richard N., Anthony Dorling, David Ayares, Michael A. Rees, Jörg D. Seebach, Jay A. Fishman, Bernhard J. Hering, and David K. C. Cooper. 2009. “Current Status of Xenotransplantation and Prospects for Clinical Application.” Xenotransplantation 16 (5) (September): 263–280. doi:10.1111/j.1399-3089.2009.00534.x.

Abstract

Xenotransplantation is one promising approach to bridge the gap between available human cells, tissues, and organs and the needs of patients with diabetes or end-stage organ failure. Based on recent progress using genetically-modified source pigs, improving results with conventional and experimental immunosuppression, and expanded understanding of residual physiologic hurdles, xenotransplantation appears likely to be evaluated in clinical trials in the near future for some select applications. This review offers a comprehensive overview of known mechanisms of xenograft injury, a contemporary assessment of preclinical progress and residual barriers, and our opinions regarding where breakthroughs are likely to occur.

Description

Research Data

Keywords

Antibody-mediated rejection, α1,3-galactosyltransferase gene-knockout, Coagulation, Genetic engineering, Pancreatic islets, pig, pig, Xenotransplantation

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories